drugset

drugset / Trial / NCT00322023

Safety and Effectiveness of D-serine in Schizophrenia

NCT00322023 ↗

Phase 2 Completed 55 enrolled Nathan Kline Institute for Psychiatric Research National Institute of Mental Health (NIMH) · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will determine whether increasing D-serine within the body will improve negative symptoms and cognitive impairments in people with schizophrenia.

Timeline

Start: 2006-03
Primary completion: 2009-01
Completion: 2009-01

Publications

Kantrowitz JT, Epstein ML, Lee M, Lehrfeld N, Nolan KA, Shope C, Petkova E, Silipo G, Javitt DC. Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms. Schizophr Res. 2018 Jan;191:70-79. doi: 10.1016/j.schres.2017.02.027. Epub 2017 Mar 18.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	D-serine	Unknown	30 mg/kg	Oral
Subject	D-serine	Unknown	60 mg/kg	Oral
Subject	D-serine	Unknown	120 mg/kg	Oral

Indications